Affordable Access

Access to the full text

Cardiac glycosides: From molecular targets to immunogenic cell death

Authors
Type
Published Article
Journal
Biochemical Pharmacology
Publisher
Elsevier
Publication Date
Feb 24, 2017
Volume
125
Identifiers
DOI: 10.1016/j.bcp.2016.08.017
Source
LBMCC
Keywords
License
Green

Abstract

Cardiac glycosides (CGs) are approved for the treatment of cardiovascular alterations and their known cellular target is the alpha subunit of the sodium (Na+)/potassium (K+)-ATPase (NKA). Pharmacologically, they represent a well-known generation of drugs for treating cardiovascular problems, thus allowing the investigation of potential dose-dependent side effects.

Report this publication

Statistics

Seen <100 times